Saquinavir: Difference between revisions
CSV import |
CSV import |
||
| Line 18: | Line 18: | ||
{{antiviral agents}} | {{antiviral agents}} | ||
{{coststubd}} | {{coststubd}} | ||
== Saquinavir == | |||
<gallery> | |||
File:Saquinavir structure.svg|Saquinavir structure | |||
File:Saquinavir ball-and-stick.png|Saquinavir ball-and-stick model | |||
File:HIV new infections and deaths 1981-2008.jpg|HIV new infections and deaths 1981-2008 | |||
</gallery> | |||
== Saquinavir == | == Saquinavir == | ||
<gallery> | <gallery> | ||
Revision as of 01:40, 20 February 2025
Saquinavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS).
Saquinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and, rarely, can lead to clinically apparent acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with saquinavir may result of an exacerbation of the underlying chronic hepatitis B or C.
Saquinavir (sa kwin' a vir) is an antiretroviral protease inhibitor that acts by binding to the catalytic site of the HIV protease, thereby preventing the cleavage of viral polyprotein precursors into mature, functional proteins that are necessary for viral replication.
Saquinavir was approved for use in the United States in 1995 and is still widely used in combination with other antiretroviral agents for the prevention and treatment of HIV infection in adults and children. Saquinavir is available under the brand name Invirase in 200 mg capsules and 500 mg tablets. It is usually used in combination with a low dose of ritonavir, which improves its pharmacokinetics and allows for twice daily dosing.
The recommended dose of saquinavir is 1000 mg in combination with 100 mg of ritonavir, both taken twice daily.
The most common side effects of HIV protease inhibitors include gastrointestinal upset, diarrhea, nausea, fatigue and, with long term use, hyperlipidemia and lipodystrophy.
Antiviral agents
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Fusion Inhibitors (HIV)
- Integrase Inhibitors (HIV)
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Interferon Based Therapies
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Combination Therapies
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza
-
Saquinavir structure
-
Saquinavir ball-and-stick model
-
HIV new infections and deaths 1981-2008
-
Saquinavir structure
-
Saquinavir ball-and-stick model
-
HIV new infections and deaths 1981-2008